Neose Technologies, Inc.

Novo Nordisk A/s

University of Alberta

Biogenerix Ag

Seneb Biosciences, Inc.

The University of British Columbia

La Jolla Pharmaceutical Company

Karl Frank Johnson

Shawn DeFrees

Daniel James Bezila

David A Zopf

Stephen A Roth

Stephen G Withers

Diane E Taylor

Paul M Simon

Marc F Schwartz

Mark Vaughan

Joanne Simala-Grant

Stephanie L Buczala

Roger A Barthelson

Aliakbar Mobasseri

David James Hakes

Shawn Defrees

Zhi-Guang Wang

Tarik Soliman

Kyle Kinealy

Xiaomei Bai

Sami Saribas

Scott Willett

David Rasko

Shawn A Defrees

Bingyuan Wu

The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.

Mutant endoglycoceramidases with enhanced synthetic activity

The present invention provides methods of refolding mammalian glycosyltransferases that have been produced in bacterial cells, and methods to use such refolded glycosyltransferases, including glycosyltransferase mutants that have enhanced ability to be refolded. The invention also provides methods of refolding more than one glycosyltransferase in a single vessel, methods to use such refolded glycosyltransferases, and reaction mixtures comprising the refolded glycosyltransferases.

Methods of refolding mammalian glycosyltransferases

The invention relates to methods of producing an O-glycosylated soluble therapeutic protein in a prokaryotic microorganism by co-expressing the therapeutic protein and a heterologous glycosyltransferase that transfers a sugar moiety to an amino acid acceptor on the therapeutic protein.

Expression of O-glycosylated therapeutic proteins in prokaryotic microorganisms

The present invention provides enhanced methods of producing soluble, active fibroblast growth factor-20 (FGF-20), FGF-21, neurotrophin-3 (NT-3), growth hormone (GH), granulocyte colony stimulating factor (G-CSF), or glucocerebrosidase proteins in microorganisms that have an oxidizing environment.

Expression of soluble therapeutic proteins

The present invention provides modifiedsialyltransferase proteins that exhibit enhanced expression as compared to its unmodified form. Nucleic acids that encode the sialyltransferase proteins are also included, as are methods to produce and use the sialyltransferase proteins.

Tagged sialyltransferase proteins

Novel synthetic glycosphingolipids and pharmaceutical compositions containing such synthetic glycosphingolipids are described. Methods of making the novel synthetic glycosphingolipid compounds and compositions as well as their use in the field of neuroprotection and cancer treatment is also described.

Ganglioside compositions and methods of use

This invention provides nucleic acid and amino acid sequences of fucosyltransferases from. The invention also provides methods to use the fucosyltransferases to synthesize oligosaccharides, glycoproteins, and glycolipids.

Synthesis of oligosaccharides, glycolipids, and glycoproteins using bacterial glycosyltransferases

This invention provides methods for modifying glycosylation patterns of glycopeptides, including recombinantly produced glycopeptides. Also provided are glycopeptide compositions in which the glycopeptides have a homogeneous glycosylation pattern.

Glycopeptide remodeling using amidases

[object Object]

The present invention relates to a method of transferring at least two saccharide units with a polyglycosyltransferase, a polyglycosyltransferase and a gene encoding such a polyglycosyltransferase.

Method of transferring at least two saccharide units with a polyglycosyltransferase

Method of transferring at least two saccharide units with a

The present invention is directed to compositions for the treatment of respiratory infections caused by a bacteria selected from the group consisting of S. pneumoniae, H. influenzae, H. parainfluenza, Burkholderia (Pseudomonas) cepacia, and a mixture thereof, comprising a binding inhibiting effective amount of the compound of Formula I, ##STR1## where R.sub.1 is H, (.beta.-1)GalNAc-, SO.sub.3 B (where B is H or a cation) or a sialic acid of Formula II; ##STR2## where R.sub.6, R.sub.7, R.sub.8, and R.sub.10 are each independently H, C.sub.1-6 acyl, lactyl, C.sub.1-6 alkyl, sulfate, phosphate, anhydro, a sialic acid of Formula II, (.alpha.-1)Fuc, (.beta.-1)Glc or (.beta.-1)Gal;

Bacterial inhibition with an oligosaccharide compound

The present invention is directed to a method of treating respiratory infections caused by a bacteria selected from the group consisting of S. pneumoniae, H. influenzae, H. parainfluenzae, Burkholderia (Pseudomonas) cepacia and a mixture thereof, by administering a binding inhibiting effective amount of the compound of Formula I, ##STR1## where R.sub.1 is H, (.beta.-1)GalNAc--, SO.sub.3 B (where B is H or a cation) or a sialic acid of Formula II; ##STR2## where R.sub.6, R.sub.7, R.sub.8, and R.sub.10 are each independently H, C.sub.1-6 acyl, lactyl, C.sub.1-6 alkyl, sulfate, phosphate, anhydro, a sialic acid of Formula II, (.alpha.-1)Fuc, (.beta.-1)Glc or (.beta.-1)Gal;

Growing community of inventors

Hatboro, PA, United States of America

Karl Frank Johnson